Head and neck cancer metastatic

6 trials 1 recruiting MedDRA PT
6 Registered trials
1 Recruiting
6 Unique sponsors
7 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
L Oncology (ATC L) 4
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (chimeric) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Phase II: 3 Phase I/II: 1 Phase I: 1 Phase I (Other): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

3 trials
  • Immutep Commercial
    EFTILAGIMOD ALFA; PEMBROLIZUMAB
    2024-510762-16-00 5 countries 2021 n=127
    Ended
  • Seagen Inc. Commercial
    PEMBROLIZUMAB; TISOTUMAB VEDOTIN
    2023-503812-34-00 4 countries 2019 n=79
    Ended
  • Charite Universitaetsmedizin Berlin KöR Academic
    AVELUMAB; CETUXIMAB
    2025-521738-27-00 1 country 2025 n=126
    Recruiting

Phase I/II

1 trial
  • Institut Gustave Roussy Academic
    DURVALUMAB; TREMELIMUMAB
    2024-514920-18-00 1 country 2017 n=61
    Ended

Phase I

1 trial

Phase I (Other)

1 trial
  • Exelixis Inc. Commercial
    IMP not specified
    2024-516477-73-00 2 countries 2018 n=320
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Exelixis Inc. Commercial 1 Phase I (Other) 0
Immutep Commercial 1 Phase II 0
Seagen Inc. Commercial 1 Phase II 0
Incyte Corp. Academic 1 Phase I 0
Charite Universitaetsmedizin Berlin KöR Academic 1 Phase II 1
Institut Gustave Roussy Academic 1 Phase I/II 0
New trials by year
2019
1
2021
1
2022
1
2025
1
← All indication landscapes